- 45 -

- A method of stimulating kidney tubule formation in a post-natal mammal, comprising administering to said mammal a substantially pure Wnt polypeptide or a Wnt agonist, wherein said Wnt
 polypeptide is not Wnt-11.
 - 2. The method of claim 1, wherein said mammal is characterized as suffering from a kidney disorder.
 - 3. The method of claim 1, wherein said mammal is an adult mammal.
- 10 4. The method of claim 2, wherein said disorder is chronic renal failure.
 - 5. The method of claim 2, wherein said disorder is renal cell carcinoma.
- 5. The method of claim 2, wherein said disorder 15 is polycystic kidney disease.
 - 6. The method of claim 2, wherein said disorder is chronic obstructive uropathy.
 - 7. The method of claim 2, wherein said disorder is virus-induced nephropathy.
- 20 8. The method of claim 7, wherein said virus is HIV-1.
 - 9. The method of claim 1, wherein said Wnt polypeptide is a Wnt-1 class polypeptide.

WO 00/61630 PCT/US99/07745

- 46 -

- 10. The method of claim 1, wherein said Wnt polypeptide is selected from the group consisting of Wnt-3a, Wnt-4, Wnt-7a, and Wnt-7b.
- 11. The method of claim 1, wherein said Wnt 5 polypeptide is Wnt-4.
 - 12. The method of claim 1, wherein said Wnt agonist is HLDAT86.
 - 13. The method of claim 1, further comprising administering a sulfated glycosaminoglycan.
- 14. The method of claim 1, wherein said Wnt polypeptide or Wnt agonist is administered locally to a renal tissue.
- 15. The method of claim 14, wherein said Wnt polypeptide or Wnt agonist administered by retrograde perfusion of said renal tissue.
 - 16. The method of claim 1, wherein said Wnt polypeptide or Wnt agonist is administered ex vivo to an explanted renal tissue.
- 17. The method of claim 1, wherein said Wnt 20 agonist is a peptide mimetic.
 - 18. The method of claim 1, wherein said Wnt polypeptide has an amino acid sequence at least 85% identical to SEQ ID NO:1, 2, 3, 4, or 5, and wherein said Wnt polypeptide induces tubulogenesis.

WO 00/61630 PCT/US99/07745

- 47 -

- 19. A method of stimulating kidney tubule formation in a post-natal mammal, comprising administering to said mammal a substantially pure nucleic acid encoding a Wnt polypeptide or a Wnt agonist.
- 5 20. An ex vivo mammalian kidney comprising an substantially pure exogenous Wnt polypeptide.